> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# IND Approved for ZioPharm CAR-T Therapy in Leukemia Patients
- URL: https://www.fdaweb.com/ind-approved-for-ziopharm-car-t-therapy-in-leukemia-patients/
- Published: 2017-05-03T12:00:00.000Z
- Updated: 2026-09-14T22:21:39.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138611

FDA has approved an investigator-initiated IND to begin a Phase 1 trial involving ZioPharm Oncology’s CD33-specific CAR-T therapy for relapsed or refractory acute myeloid leukemia (AML). The first patient is expected to be enrolled in the study in the third quarter. The CD33-specific CAR-T cells incorporate a “kill switc designed to eliminate the modified T cells under potential adverse safety conditions,” the company says. “*In vivo* preclinical animal studies have demonstrated that these CAR-T cells targeting CD33 exhibit specific killing of AML cells, eliminating disease burden, and significantly enhancing survival compared to controls...”